Nasdaq · CIK 0001598646
NERV Minerva Neurosciences, Inc.
Insider trading from SEC Form 4. Last filing Jun 5, 2026.
Minerva Neurosciences, Inc. (NERV) has 25 SEC Form 4 filings on file from 9 insiders, the latest filed on Jun 5, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
6 Form 144 notices of planned sales are on file, the latest filed Mar 31, 2026.
Last 90 days
Signals
Open-market buys and sells at Minerva Neurosciences, Inc., scored.
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 31, 2026 | Federated Hermes Kaufmann Fund II, a portfolio of Federated Hermes Insurance Series 10% Stockholder | 8,798 0.02% of outstanding | $70k | Mar 31, 2026 | $29k |
| Mar 31, 2026 | Federated Hermes Kaufmann Fund, a portfolio of Federated Hermes Equity Funds 10% Stockholder | 31,808 0.07% of outstanding | $254k | Mar 31, 2026 | $1.2M |
| Mar 31, 2026 | Federated Hermes Kaufmann Small Cap Fund, a portfolio of Federated Hermes Equity Funds 10% Stockholder | 19,838 0.05% of outstanding | $159k | Mar 31, 2026 | $743k |
| Mar 10, 2026 | Federated Hermes Kaufmann Fund II, a portfolio of Federated Hermes Insurance Series 10% Stockholder | 12,456 0.03% of outstanding | $100k | Mar 10, 2026 | none |
| Mar 10, 2026 | Federated Hermes Kaufmann Fund, a portfolio of Federated Hermes Equity Funds 10% Stockholder | 424,278 0.98% of outstanding | $3.4M | Mar 10, 2026 | none |
| Mar 10, 2026 | Federated Hermes Kaufmann Small Cap Fund, a portfolio of Federated Hermes Equity Funds 10% Stockholder | 264,615 0.61% of outstanding | $2.1M | Mar 10, 2026 | none |
Transactions
Every row filed, 25 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Hans Peter Hasler director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 5, 2026 |
| Jun 3, 2026 | Inderjit Kaul director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 5, 2026 |
| Jun 3, 2026 | David Kupfer director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 5, 2026 |
| Jun 3, 2026 | Fouzia Laghrissi-Thode director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 5, 2026 |
| Jun 3, 2026 | Remy Luthringer CEO | AGrant or award Employee Stock Option (right to buy)derivative | +1,690,700 | $0.00 | $0 | 1,690,700 | Jun 5, 2026 |
| Jun 3, 2026 | G Jan Van Heek director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 5, 2026 |
| Jun 3, 2026 | Frederick W Ahlholm SVP, CFO and Secretary | AGrant or award Employee Stock Option (right to buy)derivative | +680,000 | $0.00 | $0 | 680,000 | Jun 5, 2026 |
| Apr 21, 2026 | James Joseph O'Connor Chief Business Officer and GC | AGrant or award Employee Stock Option (right to buy)derivative | +350,800 | $0.00 | $0 | 350,800 | Apr 22, 2026 |
| Mar 31, 2026 | Inderjit Kaul director | AGrant or award Stock Option (right to buy)derivative | +12,169 | $0.00 | $0 | 12,169 | Apr 1, 2026 |
| Dec 22, 2025 | David Kupfer director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Dec 23, 2025 |
| Dec 22, 2025 | Geoff Race President | AGrant or award Employee Stock Option (right to buy)derivative | +1,500,000 | $0.00 | $0 | 1,500,000 | Dec 23, 2025 |
| Dec 22, 2025 | G Jan Van Heek director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Dec 23, 2025 |
| Dec 22, 2025 | Remy Luthringer CEO | AGrant or award Employee Stock Option (right to buy)derivative | +2,250,000 | $0.00 | $0 | 2,250,000 | Dec 23, 2025 |
| Dec 22, 2025 | Fouzia Laghrissi-Thode director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Dec 23, 2025 |
| Dec 22, 2025 | Inderjit Kaul director | AGrant or award Stock Option (right to buy)derivative | +364,504 | $0.00 | $0 | 364,504 | Dec 23, 2025 |
| Dec 22, 2025 | Hans Peter Hasler director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Dec 23, 2025 |
| Dec 22, 2025 | Frederick W Ahlholm SVP, CFO and Secretary | AGrant or award Employee Stock Option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Dec 23, 2025 |
| Nov 14, 2025 | Inderjit Kaul director | AGrant or award Stock Option (right to buy)derivative | +9,500 | $0.00 | $0 | 9,500 | Nov 18, 2025 |
| Dec 5, 2024 | Frederick W Ahlholm SVP, CFO and Secretary | AGrant or award Employee Stock Option (right to buy)derivative | +47,500 | $0.00 | $0 | 47,500 | Dec 6, 2024 |
| Dec 5, 2024 | Hans Peter Hasler director | AGrant or award Stock Option (right to buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Dec 6, 2024 |
| Dec 5, 2024 | David Kupfer director | AGrant or award Stock Option (right to buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Dec 6, 2024 |
| Dec 5, 2024 | Fouzia Laghrissi-Thode director | AGrant or award Stock Option (right to buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Dec 6, 2024 |
| Dec 5, 2024 | Remy Luthringer CEO | AGrant or award Employee Stock Option (right to buy)derivative | +105,000 | $0.00 | $0 | 105,000 | Dec 6, 2024 |
| Dec 5, 2024 | Geoff Race President | AGrant or award Employee Stock Option (right to buy)derivative | +95,000 | $0.00 | $0 | 95,000 | Dec 6, 2024 |
| Dec 5, 2024 | G Jan Van Heek director | AGrant or award Stock Option (right to buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Dec 6, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Frederick W AhlholmSVP, CFO and Secretary
- Hans Peter Haslerdirector
- Inderjit Kauldirector
- David Kupferdirector
- Fouzia Laghrissi-Thodedirector
- Remy LuthringerCEO
- James Joseph O'ConnorChief Business Officer and GC
- Geoff RacePresident
- G Jan Van Heekdirector
Questions about NERV
Answered from the filings on this page, as of the latest one.
Are insiders buying NERV?
No. In the last 90 days no insider at Minerva Neurosciences, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade NERV on the open market?
No open-market trade has been scored at Minerva Neurosciences, Inc.. The latest Form 4 on file was filed on Jun 5, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Minerva Neurosciences, Inc.?
9 people have filed a Form 4 at Minerva Neurosciences, Inc., among them Frederick W Ahlholm (SVP, CFO and Secretary), Hans Peter Hasler (director), Inderjit Kaul (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.